JW
Lv41
440 积分
2023-05-24 加入
-
Pharmacological inhibition of HPK1 synergizes with PD-L1 blockade to provoke antitumor immunity against tumors with low antigenicity
4小时前
已完结
-
PARP7 Regulates FRA1 Protein-Turnover and Thermostability: Implications for Cancer Progression and Treatment
10天前
已关闭
-
Neuroprotective treatment with the nitrone compound OKN-007 mitigates age-related muscle weakness in aging mice
26天前
已完结
-
Design, Synthesis, and Structure–Activity Relationship of Novel Pyridazinone-Based PARP7/HDACs Dual Inhibitors for Elucidating the Relationship between Antitumor Immunity and HDACs Inhibition
1个月前
已完结
-
First‐in‐Human Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E6742, a Dual Antagonist of Toll‐like Receptors 7 and 8, in Healthy Volunteers
1个月前
已完结
-
Discovery of 5-aminopyrido[2,3-d]pyrimidin-7(8H)-one derivatives as new hematopoietic progenitor kinase 1 (HPK1) inhibitors
1个月前
已完结
-
Discovery of hematopoietic progenitor kinase 1 inhibitors using machine learning-based screening and free energy perturbation
3个月前
已完结
-
UNC93B1 variants underlie TLR7-dependent autoimmunity
3个月前
已完结
-
Discovery of tricyclic PARP7 inhibitors with high potency, selectivity, and oral bioavailability
3个月前
已完结
-
Phenoxythiazoline (FTz)‐Cobalt(II) Precatalysts Enable C(sp2)‐C(sp3) Bond Formation for Key Intermediates in the Synthesis of Toll‐like Receptor 7/8 Antagonists
4个月前
已完结